川寧生物(301301.SZ):截止目前,紅沒藥醇已形成銷售約2.8噸,實現收入150萬元左右
格隆匯10月25日丨川寧生物(301301.SZ)於2023年10月24日召開業績交流會,就“請問三季度紅沒藥醇和5-羥基色氨酸的銷量、價格和訂單情況如何?對明年的銷量指引?”,公司回覆稱,公司已組建合成生物學日化市場部,在國內市場開拓方面,紅沒藥醇產品小樣已經送至終端客户手中,目前反饋情況積極良好,品質接近或部分指標優於天然紅沒藥醇。國外市場開拓方面,已通過代理商向國外客户積極送樣,產品價格緊隨巴斯夫等公司,積極開拓國內外市場。截止目前,紅沒藥醇已形成銷售約2.8噸,實現收入150萬元左右,5-羥基色氨酸目前還處於中試階段,已有中試樣品送往客户。明年合成生物學基地一期項目處於產能爬坡期,多個產品需要根據訂單切換生產,預計主要產品紅沒藥醇銷量會有大幅增長,銷量在80-100噸左右,具體的銷量還需根據市場情況而定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.